Shattuck Q3 Loss Widens to $25.2M as R&D Spending Nearly Triples
STTK has more than doubled off its 52-week low of $1.72.
Summary
Shattuck posted a Q3 net loss of $25.2 million, or $0.14 per share, versus a $10.1 million loss a year earlier, as R&D spending jumped to $21.6 million from $7.6 million. Cash and investments stood at $196.3 million at September 30, up from $86.1 million a year ago, and management says that funds operations into 2029. The quarter's real news is clinical: the company started the RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn's disease, with 12-week induction data expected in the first half of 2028, and plans to start the RECEPTIVE-HS1 Phase 2 trial in hidradenitis suppurativa in the fourth quarter of 2026 after an October IND submission. It also presented preclinical SL-846 data at UEG Week 2026 and expects initial Phase 1 data for that bispecific in 2027. The wider loss is the cost of standing up two Phase 2 programs, and with the stock at $5.50 the runway removes near-term financing pressure; the next hard checkpoints are the HS trial start this quarter and management's fireside chats at the Evercore ISI conference November 30-December 1 and the Piper Sandler conference December 2-3.
At the time of this announcement, STTK was trading at $5.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $516.9M. The 52-week trading range was $1.72 to $8.33. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.